23andMe Holding Valuation
Is ME undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of ME when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate ME's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate ME's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ME?
Key metric: As ME is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is ME's PS Ratio? | |
|---|---|
| PS Ratio | 0.4x |
| Sales | US$193.26m |
| Market Cap | US$82.00m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.1x |
| Enterprise Value/EBITDA | -0.1x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does ME's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 4.6x | ||
CCEL Cryo-Cell International | 2.1x | 1.0% | US$68.0m |
CDIX Cardiff Lexington | 13.1x | n/a | US$98.9m |
NUTX Nutex Health | 0.5x | 14.3% | US$156.0m |
PRE Prenetics Global | 2.5x | 93.6% | US$55.0m |
ME 23andMe Holding | 0.4x | n/a | US$82.0m |
Price-To-Sales vs Peers: ME is good value based on its Price-To-Sales Ratio (0.4x) compared to the peer average (4.6x).
Price to Sales Ratio vs Industry
How does ME's PS Ratio compare vs other companies in the US Healthcare Industry?
Price-To-Sales vs Industry: ME is good value based on its Price-To-Sales Ratio (0.4x) compared to the US Healthcare industry average (1x).
Price to Sales Ratio vs Fair Ratio
What is ME's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 0.4x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate ME's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Elevance Health
US$92.9b
Operates as a health benefits company in the United States.
ELV
US$400.70
7D
-5.8%
1Y
-13.9%
CVS Health
US$66.9b
Provides health solutions in the United States.
CVS
US$56.05
7D
0.4%
1Y
-17.9%
Patterson Companies
US$1.7b
Engages in the distribution of dental and animal health products in the United States, the United Kingdom, and Canada.
PDCO
US$20.90
7D
-0.7%
1Y
-34.7%